Methylphenidate - Adverse effects
Research News and Information

Saturday, November 21, 2009

[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD]

30 Aug 2009 Attention Deficit Hyperactivity Disorder (ADHD) is not only a childhood disorder but symptoms persist into adolescence and adulthood in approximately one third of the patients. Especially inattention and poor concentration impair driving performance ... Read more...

A washout period needed before switching from a neuroleptic to an amphetamine.

30 Jul 2009 (1) Abrupt replacement of risperidone with methylphenidate can lead to severe agitation in children; (2) Abruptly switching from one pharmacological class to another can lead to ... Read more...

Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.

29 Jun 2009 OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood. Principal treatment options for ADHD today include the psychostimulants, mainly methylphenidate (MPH). However, approximately 30% to ... Read more...

Latest indexed articles for 'Methylphenidate - Adverse effects'

These are the very latest articles for this heading:

• [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD] 30 Aug 2009
• Stimulant use linked to sudden death in children without heart problems. 10 Aug 2009
• A washout period needed before switching from a neuroleptic to an amphetamine. 30 Jul 2009
• Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. 29 Jun 2009
• Chronic preexposure to methylphenidate cross-sensitizes methamphetamine in male Japanese quail. 29 Jun 2009
• Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial. 29 Jun 2009
• Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. 29 Jun 2009
• Cardiovascular effects of methylphenidate. 29 Jun 2009
• [Paradoxical effect of methylphenidate in the treatment of a patient with severe traumatic brain injury] 20 Jun 2009
• Is it acceptable for people to take methylphenidate to enhance performance? No. 16 Jun 2009
• Sudden death and use of stimulant medications in youths. 13 Jun 2009
• A commentary on "A young man with acute dilated cardiomyopathy associated with methylphenidate". 5 Jun 2009
• Methylphenidate induction of complex visual hallucinations. 3 Jun 2009
• [Methylphenidate. A drug for attention deficit disorders to be used with precaution] 30 May 2009
• Transdermal methylphenidate system: old wine in a new bottle. 30 May 2009
• Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. 30 May 2009
• Attention-deficit-hyperactivity disorder: an update. 30 May 2009
• Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. 30 May 2009
• Safety of methylphenidate following traumatic brain injury: impact on vital signs and side-effects during inpatient rehabilitation. 30 May 2009
• An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. 24 May 2009

See a longer list of these articles.

Technical information about 'Methylphenidate'

Definition: A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE.

Chemical name: 2-Piperidineacetic acid, alpha-phenyl-, methyl ester

Registry Number: 113-45-1

Descriptor UI: D008774

Alternative terms: Methylphenidate; Dexmethylphenidate; Dexmethylphenidate Hydrochloride; Hydrochloride, Dexmethylphenidate; Focalin; Novartis Pharmaceutical Brand of Dexmethylphenidate Hydrochloride; Metadate; Equasym; Celltech Brand of Methylphenidate Hydrochloride; Methylphenidate Hydrochloride; Hydrochloride, Methylphenidate; Phenidylate; Ritalin; Novartis Brand 1 of Methylphenidate Hydrochloride; Ritaline; Cephalon Brand of Methylphenidate Hydrochloride; Ritalin-SR; Ritalin SR; Novartis Brand 2 of Methylphenidate Hydrochloride; Tsentedrin; Centedrin; Daytrana; Methylin; Mallinckrodt Brand of Methylphenidate Hydrochloride;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Dopamine Uptake Inhibitors; Central Nervous System Stimulants;

Tree Number: D02.241.223.601.600; D03.383.621.460;

Online Note: use METHYLPHENIDATE to search PHENIDYLATE 1978-94

History Note: PHENIDYLATE was see METHYLPHENIDATE 1978-94